Literature DB >> 12964958

P2Y(2) receptor elicits PAS-positive glycoprotein secretion from rabbit conjunctival goblet cells in vivo.

Tadahiro Murakami1, Tsutomu Fujihara, Masatsugu Nakamura, Katsuhiko Nakata.   

Abstract

We investigated in vivo whether UTP and ATP increased periodic acid and Schiff's reagent (PAS)-positive glycoprotein release from rabbit conjunctival goblet cells. Fifty microL of UTP or ATP at the concentrations of 0.003, 0.03, 0.3, 3.0, 8.5% (54 microM-154 mM) or saline were applied to rabbit eyes. Impression cytology was performed on the upper nasal bulbar conjunctiva and the cells were stained with PAS. To clarify purinergic receptor-mediated involvement in this response, suramin (1%; 7 mM), P2Y(2) antagonist and pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS, 0.01%; 167 microM), P2Y(1) antagonist were applied in the rabbit conjunctival sac for 10 min. before UTP or ATP application. Images of the specimens were taken with a digital camera mounted on a microscope and the PAS staining area was measured using an image analyzing system. UTP or ATP eye drop instillation transiently decreased the PAS staining area in a dose-dependent manner, but it gradually recovered after another 30 min. Saline instillation had no effect until 60 min. later. All of the agonists-induced declines were inhibited by pretreatment with 1% (7 mM) suramin but not 0.01% (167 microM) PPADS. UTP and ATP stimulate PAS-positive glycoprotein secretion via P2Y(2) receptor on goblet cells in the rabbit bulbar conjunctiva in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12964958     DOI: 10.1089/108076803322279390

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  9 in total

1.  Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

Authors:  Robin R Hodges; Darlene A Dartt
Journal:  Exp Eye Res       Date:  2013-08-14       Impact factor: 3.467

2.  Changes of tear film lipid layer thickness by 3% diquafosol ophthalmic solutions in patients with dry eye syndrome.

Authors:  Dong-Hyun Kang; Yong-Woo Lee; Kyu-Yeon Hwang; Kyung-Min Koh; Young-A Kwon; Byung-Yeop Kim; Sang-Wroul Song; Kook-Young Kim
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

3.  Expression of the P2Y₂ receptor on the rat ocular surface during a 1-year rearing period.

Authors:  Hidetoshi Tanioka; Yumi Kuriki; Asuka Sakamoto; Osamu Katsuta; Kouichi Kawazu; Masatsugu Nakamura
Journal:  Jpn J Ophthalmol       Date:  2014-09-02       Impact factor: 2.447

Review 4.  Lacritin and other new proteins of the lacrimal functional unit.

Authors:  Robert L McKown; Ningning Wang; Ronald W Raab; Roy Karnati; Yinghui Zhang; Patricia B Williams; Gordon W Laurie
Journal:  Exp Eye Res       Date:  2008-09-18       Impact factor: 3.467

5.  Efficacy of retinol palmitate eye drops for dry eye in rabbits with lacrimal gland resection.

Authors:  Akito Odaka; Hiroshi Toshida; Toshihiko Ohta; Nobuhito Tabuchi; Daisuke Koike; Chikako Suto; Akira Murakami
Journal:  Clin Ophthalmol       Date:  2012-10-01

Review 6.  P2Y2 receptor agonists for the treatment of dry eye disease: a review.

Authors:  Oliver C F Lau; Chameen Samarawickrama; Simon E Skalicky
Journal:  Clin Ophthalmol       Date:  2014-01-30

Review 7.  Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension.

Authors:  Mazen Shihan; Tatyana Novoyatleva; Thilo Lehmeyer; Akylbek Sydykov; Ralph T Schermuly
Journal:  Int J Environ Res Public Health       Date:  2021-10-20       Impact factor: 3.390

8.  Immunolocalisation of P2Y receptors in the rat eye.

Authors:  Jesús Pintor; Jesús Sánchez-Nogueiro; Marta Irazu; Aranzazu Mediero; Teresa Peláez; Assumpta Peral
Journal:  Purinergic Signal       Date:  2004-12       Impact factor: 3.765

9.  Adherence to Eye Drops Usage in Dry Eye Patients and Reasons for Non-Compliance: A Web-Based Survey.

Authors:  Miki Uchino; Norihiko Yokoi; Jun Shimazaki; Yuichi Hori; Kazuo Tsubota
Journal:  J Clin Med       Date:  2022-01-12       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.